Business● LowSep 8 · Sep 8, 2026, 8:33 AM
Upstream Bio stock jumps 8% on Phase 2 severe asthma data
GlobeAlert Desk · curated from Seeking Alpha Tech · global
Upstream Bio's stock increased by 8% following the release of Phase 2 data related to severe asthma treatment. This indicates a positive market reaction to the clinical trial results.
GlobeAlert aggregates and classifies open sources; the story above belongs to its publisher. Summaries are machine-generated from the source text. How we score stories.
GlobeAlert context
What the desk knows about this story
Threat level
0 Low
Scored from severity, scale, escalation potential and source agreement. Below the alert threshold.
Sources
1 publisher
Single-source so far. Treat details as unconfirmed until more publishers report.
Category
Business
Not flagged as developing.
More in Business
BusinessnowMunicipal Securities Underwriters Pay a Total of $325,000 in FinesSECBusinessnowSEC CHAIRMAN ARTHUR LEVITT, IOWA OFFICIALS TO HOLD INVESTORS’ TOWN MEETING IN DES MOINESSECBusiness31m agoStarwood Capital teams up with Trez Capital on U.S. residential land financingSeeking Alpha TechBusiness31m agoPortugal signs TAP sale contract with Lufthansa, pledging to keep airline PortugueseEuroNews [en]